JDRF along with the Helmsley Charitable Trust has partnered with Medtronic for the JDRF-HCT Sensor Initiative, which is targeted at continuous glucose monitoring (CGM) precision and consistency for sophisticated artificial pancreas systems.
This partnership will boost the development of Medtronic's novel redundant sensor system integrating two unique sensing technologies in one device. The JDRF-HCT Sensor Initiative was begun to speed up the development and delivery of high-precision and consistent glucose sensors. Glucose control of people with type 1 diabetes is helped by today's CGM devices.
According to Jeffrey Brewer, President and Chief Executive Officer of JDRF, in order to realize artificial pancreas the need for precise and consistent sensor technology is mandatory.
According to David Panzirer, Helmsley Charitable Trust, the main focus is lessening the burden and enhancing the quality of life of people living with type 1 diabetes and offers an opportunity for rapid development of effective and precise tools to assist day-to-day insulin management.
The orthogonally redundant sensor system will integrate a glucose oxidase (GOX) sensor and the standard technology used in CGM systems along with an optical sensor to give exact glucose values. This combination will make the two sensors work as check and balance for safe and consistent glucose measurements for an artificial pancreas system.
President of the Diabetes business of Medtronic Katie Szyman stated that by enhancing sensor precision and consistency, both the organizations will be able to fulfil their mission of helping diabetics to lead a normal healthy life.
CGM devices have dual features that include taking a real-time snapshot of the glucose level of a person with diabetes and also offering information on glucose movement. The device gives warning about the level of glucose to be high or low. CGM will reduce and control the frequency of high and low blood sugars when used constantly. Today, these sensors are used as part of artificial pancreas systems in reducing the amount of high and low blood sugar people. Artificial pancreas systems will restore non-diabetes like glucose levels in future. Medtronic lead the pathway for artificial pancreas systems.